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Available online 13 May 2016Spasticity, muscle stiffness and contracture cause severe disability after central nervous system injury. However,
current treatment options for spasticity produce muscle weakness which can impede movement, and do not di-
rectly address muscle stiffness. Here we propose that the accumulation of hyaluronan within muscles promotes
the development of muscle stiffness, and report that treatment with the enzyme hyaluronidase increases upper
limb movement and reduces muscle stiffness without producing weakness. 20 patients with unilateral upper
limb spasticity received multiple intramuscular injections of human recombinant hyaluronidase with saline at
a single visit. The safety and efﬁcacy of the injections, passive and active movement, and muscle stiffness at
eight upper limb joints were assessed at four time points: pre-injection (T0), within 2 weeks (T1), within 4–
6 weeks (T2), and within 3–5 months post-injection (T3). There were no clinically signiﬁcant adverse effects
from the injections. Passive movement at all joints, and active movement at most joints increased at T1, and
persisted at T2 and T3 for most joints. The modiﬁed Ashworth scores also declined signiﬁcantly over time
post-injection. Hyaluronidase injections offer a safe and potentially efﬁcacious treatment for muscle stiffness in
neurologically impaired individuals. These results warrant conﬁrmation in placebo-controlled clinical trials.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Case series1. Introduction
Spasticity is a commonmovement disorder after neurologic injury of
cerebral and spinal origin such as stroke, traumatic brain injury, brain
tumor, cerebral palsy, spinal cord injury, and multiple sclerosis. Upper
limb spasticity is associated with reduced functional independence
and a four-fold increase in direct care costs during the ﬁrst year post-
stroke alone (Lundstrom et al., 2010). The prevalence of spasticity in-
creases over time, contributing to further disability long after the neuro-
logic injury (Lundstrom et al., 2008). Spasticity is challenging to treat
because the underlying neural and non-neural mechanisms and their
interactions are not fully understood.
The neural mechanism underlying spasticity is hyper-excitability
of the stretch reﬂex due to disinhibition of cortical inﬂuences on spi-
nal cord circuitry, which results in velocity-dependent increase in
tonic stretch reﬂexes (Lance, 1980). However, many patients with
spasticity do not show any signs of hyperreﬂexia (Sinkjaer andh Floor, New York, NY 10016,
van).
to all the data in the study and
lication.
. This is an open access article underMagnussen, 1994). Instead, muscle stiffness, deﬁned here as in-
creased resistance to passive movement, is the most common pre-
senting sign in individuals with spasticity (Sheean and McGuire,
2009). Muscle stiffness adds further insult to the underlying weak-
ness. It both prevents full passive movement (leading to abnormal
posturing that can become ﬁxed over time) and makes active move-
ment more difﬁcult in patients who are already weak from the neu-
rologic injury. Non-neural peripheral mechanisms are thought to
cause muscle stiffness (Burke et al., 2013; Stecco et al., 2014), al-
though this has not been shown conclusively.
Current treatment options for spasticity include oral medications
such as benzodiazepines, baclofen, and tizanidine that are central ner-
vous system depressants used to suppress spinal hyper-excitability,
and local injections of botulinum toxin used to suppress muscle over-
activity. Whereas the oral medications can produce cognitive deﬁcits,
fatigue, and muscle weakness, botulinum toxin injections produce
focal muscle weakness (Phadke et al., 2015). It is thus necessary to care-
fully balance the risks and beneﬁts of treatment, which often remains
inadequate. Furthermore, these treatments do not directly addressmus-
cle stiffness.
Here, we propose the Hyaluronan Hypothesis, which postulates that
the accumulation of hyaluronan within muscles promotes the develop-
ment of muscle stiffness. We report that the enzyme hyaluronidase,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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use, increases both passive and active joint movement, and reduces
muscle stiffness in individuals with upper limb spasticity. These
results ﬁll a critical gap in the understanding of muscle stiffness,
and present a promising treatment for a vexing and widespread
problem.1.1. The Hyaluronan Hypothesis
Paralysis and immobility from central nervous system injury leads to
rapid atrophy of muscle ﬁbers (Springer et al., 2014), with a relative in-
crease in the proportion of extracellular matrix, particularly in the peri-
mysium surrounding the neurovascular tissues (de Bruin et al., 2014).
Hyaluronan, a non-sulfated high molecular weight glycosaminoglycan,
is particularly abundant around the endomysium, perimysium and epi-
mysium ofmuscles (Piehl-Aulin et al., 1985; Laurent et al., 1991),where
it provides lubrication to facilitate sliding andmyofascial force transmis-
sion within and betweenmuscles (Huijing and Jaspers, 2005). The con-
centration of hyaluronan can increase in serum, due to increased
production after cerebral injury (Al'Qteishat et al., 2006), and in
muscles from immobility (Okita et al., 2004), due to increased pro-
duction, and/or decreased degradation (Jenkins et al., 2004). At
high concentrations, hyaluronan itself, as well as protein-crosslinked
networks or ﬁbrillar assemblies of hyaluronan, can dramatically in-
crease the viscoelasticity of the extracellular matrix (Matteini et al.,
2009; Cowman et al., 2015); this decreases sliding of muscle ﬁbers
and reduces force transmission (Purslow, 2010), leading to muscle
shortening.
The shortening may predominate in muscles with large myofascial
expansions (Stecco, 2015) such as the pectoralis major, the biceps
brachii, and pronator teres, connecting them together and leading
to posturing of the upper limb in a typical ﬂexor synergy pattern
characterized by shoulder internal rotation, elbow ﬂexion, and fore-
arm pronation. Untreated and unchecked, this abnormal chronic
posturing can lead to ﬁbrosis and contracture. In fact, the accumula-
tion of hyaluronan signals ﬁbrosis (Jenkins et al., 2004). The aggrega-
tion of hyaluronan can disturb the balance of forces between the
agonist and antagonist muscles leading to co-contraction, muscle fa-
tigue, and excessive torques during movement (Hufschmidt and
Mauritz, 1985). Thus the Hyaluronan Hypothesis provides a biome-
chanical explanation of how non-neural factors contribute to the de-
velopment of muscle stiffness.
To test the Hyaluronan Hypothesis, we used the enzyme hyal-
uronidase to hydrolyze hyaluronan, reduce its molecular weight,
and lower the viscosity of the extracellular matrix (Cowman et al.,
2015). Hyaluronidase modiﬁes the permeability of connective tissue
through the hydrolysis of hyaluronan by splitting the glucosaminidic
bond between C1 of an N-acetylglucosamine moiety and C4 of a glu-
curonic acid moiety. This temporarily decreases the viscosity of the
extracellular matrix. The purpose of this case series is to describe
the safety, tolerability, and preliminary efﬁcacy of intramuscular in-
jections of off-label human recombinant hyaluronidase-saline injec-
tions in increasing passive and active joint movement and reducing
upper limb muscle stiffness in patients with cerebral injury. Human
recombinant hyaluronidase has been FDA-approved since 2005 as a
tissue permeability modiﬁer. It is currently indicated as an adjuvant
in subcutaneous ﬂuid administration for achieving hydration, to in-
crease the dispersion and absorption of other injected drugs, such
as cancer chemotherapeutics, and in subcutaneous urography for
improving resorption of radiopaque agents.
We present evidence that intramuscular injections of off-label
human recombinant hyaluronidase offer a safe and potentially efﬁca-
cious treatment for muscle stiffness that can increase passive and active
joint movement, without producing weakness, in individuals with neu-
rologic injury.2. Methods
2.1. Patients
FromMay 2014 to September 2015, twenty patients (13 male and 7
female) between 10–77 years with moderately severe upper limbmus-
cle stiffness in more than one joint, consented to and received off-label
injections of recombinant hyaluronidase in combination with preserva-
tive-free normal saline, in the outpatient hand clinic at the Hospital for
Joint Diseases, New York University Langone Medical Center. The pa-
tients had exhausted all available options with limited beneﬁt, or were
referred by providers seeking this speciﬁc off-label treatment. The insti-
tutional reviewboard approved the case series (# i15-00333). All proce-
dures were performed in accordance with the Guidelines for Good
Clinical Practice as issued by the International Conference on Harmoni-
zation of Technical Requirements for Registration of Pharmaceuticals for
Human Use. The investigation and the use of patient data for research
purposes were in accordancewith the Declaration of theWorldMedical
Association, and the study was performed in accordance with ethical
standards on human experimentation as per the Helsinki Declaration.
The inclusion criteria for the present case serieswere: informed con-
sent for the procedure and for documentation of video recordings of
jointmovement for clinical and academic purposes, andmoderately se-
vere muscle stiffness in more than one joint of a single upper limb de-
ﬁned by a modiﬁed Ashworth scale (MAS) score of ≥2. The modiﬁed
Ashworth scalemeasures resistance to passivemovement and is a com-
mon clinically used measure of muscle stiffness rather than spasticity.
Exclusion criteria were severe sensory aphasia, bilateral upper limb
weakness precluding compliance with a home exercise program using
the unaffected limb tomobilize the affected limb, concurrent treatment
of spasticity with other injectable agents such as botulinum toxin injec-
tions, and recent changes in the treatment of spasticity or underlying
medical problems. Initial suitability for the injections was assessed by
obtaining a history of known hypersensitivity to eggs or vaccines pro-
duced in the same manner as human recombinant hyaluronidase. The
20 cases are described in Table 1.
2.2. Injection With Human Recombinant Hyaluronidase
Hyaluronidase is supplied as a sterile, clear, colorless, non-preserved,
ready-for-use solution. Each mL contains 150 USP units of recombinant
human hyaluronidasewith 8.5mg sodium chloride, 1.4mgdibasic sodi-
umphosphate, 1mgalbumin human, 1.5mg L-methionine, 0.2mgpoly-
sorbate 80, and hydrochloric acid and sodium hydroxide added for pH
adjustment; it has a pH of ~7.0 and an osmolality of 280–340 mOsm/
kg. Given that hyaluronidase is known to be antigenic, a preliminary
skin test for hypersensitivity to human recombinant hyaluronidase
was performed. An intradermal injection of approximately 0.02 mL (3
units) of a 150 units/mL solution was injected. No erythema, itching,
or wheal was noted in or around the injection site at 5 or 20 min in
any of the patient's injected. There are no reported contraindications
to intramuscular injection of hyaluronidase provided routine precau-
tions to avoid intravascular injections are followed (Moore, 1950). The
use of intramuscular procaine and hyaluronidasewas previously report-
ed for the treatment for spastic ﬂatfoot (Locke, 1952). The dose of intra-
muscular hyaluronidase was determined according to each patient's
pattern and extent of muscle stiffness, but the maximum dose used in
this cohort was 600 IU, with no N75 IU injected into a single site. The
dosage selected is well below the threshold of toxicity of hyaluronidase
(Seifter, 1950).
Hylauronidase was mixed with saline in a 1:1 ratio, with 1 mL
(150 IU) of hyaluronidase diluted with 1 mL of normal saline. The typi-
cal recommended dose of hyaluronidase is 150 IU. We chose to dilute it
further because the modiﬁcation in tissue permeability induced by the
administration of hyaluronidase is inﬂuenced not only by enzyme con-
centration, but also by the volume and pressure of the injection
Table 1
Characteristics of patients.
Case
#
Age
(years) Sex
Side of
hemiparesis Etiology
Time
since
injury
(months)
Prior
treatment
Dose
injected
(IU)/#
sites
Dose
per
weight
IU/kg Muscles injected
Compliance
with exercise
program
1 67 Male Right Ischemic stroke 29 Botulinum
Toxin
450/6 5.09 Pectoralis minor, triceps, pronator teres, ﬂexor carpi
radialis, extensor carpi ulnaris, extensor digitorum
communis
Non-compliant
2 48 Female Right Hemorrhagic
stroke
64 Botulinum
Toxin
450/6 8.65 Pectoralis minor, pronator teres, ﬂexor carpi radialis,
extensor carpi ulnaris, ﬂexor digitorum, extensor
digitorum communis
Non-compliant
3 59 Male Left Ischemic stroke 61 Botulinum
Toxin
450/6 5.51 Pectoralis minor, pronator teres, ﬂexor carpi radialis,
extensor carpi ulnaris, ﬂexor digitorum, extensor
digitorum communis
Compliant
4a 53 Female Left Hemorrhagic
stroke
54 Botulinum
Toxin
450/7 5.10 Pectoralis minor, biceps brachi, pronator teres, ﬂexor
carpi radialis, extensor carpi ulnaris, extensor
digitorum communis, abductor pollicis
Non-compliant
5a 66 Male Right Hemorrhagic
stroke
41 Botulinum
Toxin
450/6 4.10 Pectoralis minor, biceps brachi, pronator teres, ﬂexor
carpi radialis, extensor carpi ulnaris, extensor
digitorum communis
Non-compliant
6 43 Female Left Ischemic stroke 45 None 450/6 7.87 Pectoralis minor, brachialis, pronator teres, ﬂexor
digitorum, extensor digitorum communis, palmar
aponeurosis
Compliant
7 43 Male Right Ischemic stroke 10 Botulinum
Toxin
600/8 7.08 Pectoralis minor, teres major, pronator teres, ﬂexor
carpi radialis, extensor carpi ulnaris, ﬂexor digitorum,
extensor digitorum communis, palmar aponeurosis
Compliant
8 59 Male Right Ischemic stroke 24 Botulinum
Toxin
600/8 6.58 Pectoralis minor, teres major, pronator teres, ﬂexor
carpi radialis, extensor carpi ulnaris, extensor
digitorum communis, ﬂexor digitorum, palmar
aponeurosis
Compliant
9a 64 Male Right Hemorrhagic
stroke
85 None 600/8 7.16 Pectoralis minor, biceps brachi, pronator teres, ﬂexor
carpi radialis, extensor carpi ulnaris, ﬂexor digitorum,
extensor digitorum communis, palmar aponeurosis
Compliant
10 15 Male Right Ischemic stroke
(carotid
dissection)
5 None 600/8 10.24 Pectoralis minor, biceps brachi, brachialis, pronator
teres, ﬂexor carpi ulnaris, ﬂexor digitorum, extensor
digitorum communis, palmar aponeurosis
Compliant
11 11 Female Left Cerebral palsy 114 Botulinum
Toxin
450/7 14.66 Pectoralis major, biceps brachi, pronator teres, ﬂexor
carpi ulnaris, extensor carpi radialis, ﬂexor digitorum,
palmar aponeurosis
Non-compliant
12 38 Female Right Ischemic stroke 18 None 600/8 9.84 Pectoralis minor, biceps brachi, brachialis, pronator
teres, ﬂexor carpi ulnaris, ﬂexor digitorum, extensor
digitorum communis, palmar aponeurosis
Compliant
13a 10 Male Right Cerebral palsy 152 Botulinum
Toxin
300/6 5.55 Pectoralis minor, biceps brachi, ﬂexor carpi radialis,
ﬂexor carpi ulnaris, ﬂexor digitorum, extensor
digitorum communis
Non-compliant
14 39 Male Left Hemorrhagic
stroke
35 Botulinum
Toxin
450/9 6.94 Pectoralis minor, biceps brachi, brachialis, pronator
teres, ﬂexor carpi ulnaris, extensor digitorum
communis, palmar aponeurosis, interosseus III-IV and
IV-V
Compliant
15 11 Male Right Brain tumor
resection
8 None 450/9 10.54 Pectoralis minor, biceps brachi, ﬂexor carpi ulnaris,
ﬂexor carpis radialis, ﬂexor digitorum, extensor
digitorum communis, palmaris aponeurosis,
interosseus III-IV and IV-V
Compliant
16 10 Female Right Stroke (AVM
rupture)
17 None 300/5 10.38 Pronator teres, brachialis, extensor carpi ulnaris,
ﬂexor digitorum, hypothenar eminence
Compliant
17 15 Female Right Brain tumor
resection
13 Botulinum
Toxin
600/9 9.48 Levator scapula, pectoralis minor, biceps brachi,
brachioradialis, pronator teres, ﬂexor carpi ulnaris,
extensor carpi radialis, ﬂexor digitorum, extensor
digitorum communis, palmar aponeurosis
Compliant
18 58 Male Right Hemorrhagic
stroke
12 None 600/8 8.10 Romboid minor, pectoralis minor, biceps brachi,
brachialis, pronator teres, ﬂexor carpi ulnaris, ﬂexor
digitorum, extensor digitorum communis
Non-compliant
19a 77 Male Left Ischemic stroke 19 None 450/5 4.72 Posterior deltoid, pectoralis minor, pronator teres,
ﬂexor carpi radialis, extensor digitorum communis
Compliant
20 37 Male Right Radiation-induced
vasculitis
7 Botulinum
Toxin
600/9 8.82 Levator scapula, pectoralis minor, brachialis, pronator
teres, ﬂexor carpi ulnaris, ﬂexor digitorum, extensor
digitorum communis, abductor pollicis, palmar
aponeurosis
Compliant
a Patients that did not receive subsequent hyaluronidase injections.
308 P. Raghavan et al. / EBioMedicine 9 (2016) 306–313(Hechter, 1947). Dilution also resulted in a lower dosage overall across
all the muscles injected. The dilution was constant across all patients
and a 0.7 mm 30G needle was used for all the injections. The skin was
cleaned with antiseptic swabs, and the injections were administered
using sterile aseptic technique by the same operator (PR). Surface ana-
tomical landmarks were used to locate the muscles injected andprecautions were taken to avoid intravascular injection. Synergistically
actingmuscles in one ormore spatial planes that appeared to contribute
most to the stiffness along the myofascial chain of the upper limb
(Stecco, 2015) were selected for injection. Fig. 1 shows the most com-
mon muscles injected across all patients. Patients were advised to use
a warm compress for local soreness around the injections sites. Given
Fig. 1.Muscles injected with Human Recombinant Hyaluronidase. Synergistically acting
muscles contributing to the stiffness along the myofascial chain of the upper limb were
selected for injection with Hylauronidase mixed with normal saline in a 1:1 ratio.
Table 2
Home exercise program.
Joint Exercise
#
Repetitions
Shoulder
ﬂexion-extension
While lying down hold the pipe in both
hands, raise arms up above the head and
then down
20
While seated hold the pipe in both hands,
raise arms up above the head and then
down
20
Elbow
ﬂexion-extension
While seated hold the pipe in both hands,
bring arm outward from the chest and then
inward
20
Forearm
pronation-supination
Hold pipe from underneath with
unaffected hand, and twist the affected
forearm to bring it palm up as far as it will
go
20
Wrist
ﬂexion-extension
Fix the upper arm to the side of the body or
place the forearms on an arm chair. Hold
the pipe with both hands and raise the
wrist up and down
20
Finger
extension-abduction
Bring hands into prayer position with
ﬁngers of the unaffected hand opposing the
same ﬁnger of the affected hand, separate
the ﬁngers repeatedly
20
All patients were prescribed a daily home-exercise program and compliance was docu-
mented in the medical chart. They were asked to hold a pipe (or stick), approximately
shoulder width in length, with both hands and perform the movements listed. Here the
unaffected arm guides and facilitates the movements of the affected arm.
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stiffness, the patientswere encouraged to continue current therapy, and
were prescribed a home exercise program of stretching and passive
movements for the affected upper limb (Table 2).
2.3. Assessments
Patients underwent a thoroughneurologic andmusculoskeletal exam
to document the extent of passive and active movement restriction and
muscle stiffness in the affected upper limb at four time-points: pre-injec-
tion (T0), and post-injection within 2 weeks (T1), between 4–6 weeks
(T2) and within 3–5 months (T3). Patients #1–6 (Table 1) were closely
monitored within 1–3 days after the injections to examine the time of
onset of therapeutic effect, if any. Safety was assessed by examination
for adverse events and clinically signiﬁcant changes in vital signs (body
temperature, diastolic and systolic pressure, heart rate) immediately
post-injection and over the period of follow-up. Adverse events were
sought through interviews, during which patients were encouraged to
report any problems. Each patient was assessed by the same physician
throughout the course of treatment. All complaints were also assessed
by an unbiased clinic nurse and documented in the medical record.
Passive and active movements were measured from video record-
ings of eight joint movements: shoulder abduction and forearm prona-
tion and supination (in the frontal plane), and shoulder forward ﬂexion,
elbow ﬂexion and extension, and wrist ﬂexion and extension (in the
sagittal plane), taken at each visit. The movements were recorded
with the camera facing perpendicular to the plane of the movement.
Eachmovementwas repeated three times passively, andwhen possible,
actively. For the ﬁrst few patients who had little ability tomove actively(#1–3, 5, and 6),we did not anticipate any changes in activemovement;
therefore these were not recorded. Finger and hand movements were
recorded for many patients, but these could not be analyzed consistent-
ly. For examples, see videos of passive and activemovements (Videos 1–
5, submitted with informed consent from patients). Joint excursions
were extracted from the videos using commercially available video
analysis software (Dartﬁsh 7.0), which enables themeasurement of an-
gular movements digitally for quantitative clinical movement analysis.
It is found to have moderate to excellent reliability for measurement
of upper limb movement amplitude (interclass correlation coefﬁcient,
ICC = 0.98–0.99) (Melton et al., 2011), and inter-rater reliability for
functional upper limb movement (ICC = 0.68–1.00) (Khadilkar et al.,
2014). We have further validated this method with 3-dimensional mo-
tion analysis and conventional goniometry in the clinical research labo-
ratory (unpublished data). However, the quality of the movements, the
degree of compensationwhen isolatedmovements are not possible, and
the angle of the camera can produce errors in determination of the ex-
cursions, particularly for forearm pronation and supination. The tech-
nique for measurement of forearm pronation and supination using a
camera placed in front of the forearm tended to overestimate the
angle of excursion, which were therefore capped at 100°. To control
for measurement errors and inadvertent bias, the best of the three trials
performed was evaluated. Also, two authors (AS and MM) indepen-
dently extracted the joint excursions from the same videos and the de-
gree of correlation between their measurements was assessed.
Muscle stiffness, deﬁned as the resistance to passivemovement, was
assessed with the modiﬁed Ashworth scale (MAS) at each time point.
The modiﬁed Ashworth scores do not take the velocity dependency of
the resistance to passive movement into account, and it is recommend-
ed that this scale should no longer be used to measure spasticity
(Fleuren et al., 2010). However, in the clinical setting for this case series,
the Ashworth scores were a useful tool tomeasuremuscle stiffness. The
scoreswere recorded in themedical chartwhere theywere extracted by
one author who was not involved in the care of the patients (MM).
2.4. Statistical Analysis
Data analysis was performed using Rstudio (version 0.99). Due to
the small sample size, the ordinal nature of the modiﬁed Ashworth
310 P. Raghavan et al. / EBioMedicine 9 (2016) 306–313scale, and to avoid violation of normality assumption, nonparametric
tests were used for inference for the three outcome measures. The
Wilcoxon-Mann-Whitney test was used to assess changes in short-
term and long-term outcomes post-injection. Hommel's adjusted p-
values were used to control for multiple hypothesis testing (Hommel,
1988). Spearman and Kendall tests were used to assess the correlation
between pre-injection measurements, dosage, age, gender, time since
neurological injury, compliance with home exercise program, short-
term (T1–T0) and long-term (T3–T0) change in passive and active
movement, and modiﬁed Ashworth scores. Mean and standard devia-
tion are reported for the continuous data (passive and active move-
ment) and median and interquartile range, and proportion of scores is
reported for the ordinal data (modiﬁed Ashworth scores). To control
for investigator bias in extraction of joint movement from the videos,
two raters independently measured the range of motion for each sub-
ject at every joint. Given that the joint movements independently ex-
tracted by the two investigators were highly correlated (Pearson's
correlation coefﬁcient = 0.98, weighted Kappa coefﬁcient = 0.97),
their average was used in the statistical analyses. To further control in-
vestigator bias and manage conﬂict of interest, the ﬁndings were
reviewed by an independent third-party with expertise in the ﬁeld
who is not associated with New York University.
2.5. Role of the Funding Source
No funding or drug was provided by any pharmaceutical company
for this case series. The drug was obtained from the hospital pharmacy
for off-label clinical use. The corresponding author had full access to
all the data in this study and had ﬁnal responsibility for the decision to
submit for publication.
3. Results
All patients (n = 20) were assessed pre-injection (T0) and within
2 weeks post-injection (T1). The mean time for post-injection assess-
ments was 7 (SD 4) days. All patients tolerated the injections without
immediate adverse effects. None of the patients demonstrated a hyper-
sensitivity reaction to the skin test. The most common adverse reaction
was soreness at the injection sites with onset within 24 h of the injec-
tion, lasting 24–48 h. The mean time for ﬁrst post-injection follow up
(T2) was 43 (SD 15) days, and it was 96 (SD 39) days for the second
post-injection follow up (T3). Three patients (#13, 17, and 19) did not
present for follow up within the T2 and T3 time frame. Patients #13
and 17 did not experience any adverse effects. Patient #19 experienced
a delayed hypersensitivity reaction characterized by a pruritic rash over
the injected areas on post-injection day two, which subsided on treat-
ment with oral diphenhydramine and topical 1% hydrocortisone over
7 days. Four patients (#1, 2, 4, and 7) did not present for follow-upwith-
in the T3 time frame. Patient #1 developed an unrelated wound on his
back from a burn, patient #2 did not experience any adverse effects, pa-
tient #4 had an unrelated fall with a humeral fracture, and patient #7
had an unrelated fall from a treadmill. The patients subsequently healed
and were followed in the clinic. Of note, 15 of the 20 patients (Table 1)
voluntarily received subsequent treatmentwith hyaluronidase after the
period of follow-up speciﬁed in this report.
The passive movement increased signiﬁcantly at all joints at T1, and
persisted at T2 and T3 for all joints, except for elbowﬂexion and forearm
supination (Table 3). Note that the passive range of motion for elbow
extension and forearm supination for most of the patients was already
within 10% of the maximum possible range at T0 (see Appendix A for
ﬁgures of individual subject data). For elbow extension the change in
passive movement was negatively correlated with the pre-injection
movement; the greater the pre-injection elbow extension, the smaller
its increase post-injection in both the short-term (r = −0.86,
p b 0.001) and long-term (r=−0.70, p=0.025). However, for forearm
supination the opposite was seen; the more restricted the forearmsupination pre-injection at T0, the smaller its increase post-injection
in the short-term (r = 0.57, p = 0.03) (Table 4).
Active movement showed more variability across patients. For pa-
tients who could perform active movements, the mean extent of move-
ment increased signiﬁcantly at all joints in the short-term, except for
elbow extension, forearm pronation, and wrist extension (Table 3).
However, over the long-term, the increase was signiﬁcant at all joints
except wrist extension. The change in active movement was negatively
correlated with the pre-injection movement; the more restricted the
pre-injection movement the greater its increase post-injection in the
short-term for elbow ﬂexion (r =−0.62, p = 0.004), and in the long-
term for elbow ﬂexion (r = −0.58, p = 0.04), forearm pronation
(r = −0.65, p = 0.017), and wrist ﬂexion (r = −0.68, p = 0.011)
(Table 4).
The median modiﬁed Ashworth scores decreased signiﬁcantly
across all the joint movements from pre- to post-injection assessments
(Table 3). The change in stiffness was negatively correlatedwith the de-
gree of pre-injection stiffness. The greater the pre-injection scores, the
smaller the change for most movements (except shoulder ﬂexion and
wrist extension) in the short-term, and for shoulder abduction
(r =−0.84, p b 0.001), elbow extension (r =−0.85, p b 0.001), and
forearm supination (r = −0.67, p = 0.013) in the long-term (Table
4). Table 5 shows that the modiﬁed Ashworth scores across all move-
ments and subjects reduced from a score of 2 (51%) and 3 (44%) at T0
to mostly 0 (48%) and 1 (30%) at T1.
Further correlation analyses showed that neither the short-term nor
the long-term changes in passive or active movement, or modiﬁed
Ashworth scores were signiﬁcantly correlated with patients' character-
istics such as age, sex, side of hemiparesis, etiology, time since injury,
prior treatment, absolute or weight-adjusted dose of hyaluronidase,
number of sites injected, or compliance with the exercise program.4. Discussion
In this case series, we report that intramuscular injections of the en-
zyme hyaluronidase increased passive and active joint movement and
reduced muscle stiffness at upper limb joints in patients with spasticity
of cerebral origin. The effect of treatment remained over at least three
months of follow-up. These results suggest that accumulation of
hyaluronan within muscles promotes the development of muscle stiff-
ness in individuals with neurologic injury, and that intramuscular deliv-
ery of hyaluronidase is a promising direct treatment formuscle stiffness.
The injections were safe and well tolerated, and without clinically sig-
niﬁcant adverse effects. Most importantly, the treatment did not pro-
duce weakness, which is a common adverse effect with current
treatment options for spasticity (Phadke et al., 2015). Side effects of
muscle weakness and fatigue are major impediments to recovery in pa-
tients with neurologic injury. The ability of hyaluronidase to reduce the
resistance to movement without producing weakness suggests that it
can potentially facilitate recovery of function after neurologic injury.
There is no direct evidence yet that the change in mechanical prop-
erties of spasticmuscles is due to the accumulation of hyaluronan.How-
ever, a study by Okita et al. (2004) showed that immobilization of the
rat ankle joint led to increased hyaluronan accumulation in the
endomysium of the rat soleus muscle compared to controls within
1 week, with concomitant decrease in sarcomere length. This was
followed by subsequent change in the arrangement of collagen ﬁbrils
and reduction in ankle range of motion. The authors suggested that in-
creased hyaluronan in muscular tissue may induce muscle stiffness.
There is now emerging evidence that the accumulation of hyaluronan
precedes ﬁbrosis in several organs including the lung, kidney, and
liver (Bensadoun et al., 1996; Evanko et al., 2015; Jun et al., 1997;
Hernnas et al., 1992; Halfon et al., 2005). Although themechanisms un-
derlying changes inmuscle due tomechanical immobilization and spas-
tic paralysis may be different, immobility is a consequence of spastic
Table 3
Mean (SD) passive and active movement and median (IQR) modiﬁed Ashworth score at each time point and signiﬁcance of change.
Shoulder ﬂexion
(max 180°)
Shoulder abduction
(max 180°)
Elbow ﬂexion
(max 150°)
Elbow extension
(max 180°)
Forearm pronation
(max 100°)
Forearm supination
(max 100°)
Wrist ﬂexion
(max 90°)
Wrist extension
(max 90°)
Passive movement
T0 132.85 (30.82) 131.3 (28.82) 142.3 (13.40) 173.35 (12.94) 88.4 (13.06) 82.3 (25.88) 72 (11.74) 47.2 (21.35)
T1 148.75 (26.95) 149.1 (27.94) 146.7 (11.66) 176.55 (10.06) 93.95 (8.40) 91.35 (13.13) 78.7 (9.66) 65.75 (22.62)
T1–T0 (n =
20) p-value
b0.001 b0.001 0.03 0.02 0.004 0.02 0.001 b0.001
T2 149.88 (24.02) 150.65 (32.44) 147.35 (11.32) 177.82 (5.75) 93.76 (9.25) 91.18 (16.88) 78.82 (10.99) 62.47 (18.36)
T3 151.38 (29.04) 160.85 (22.59) 147.92 (14.44) 178.85 (3.0) 94.38 (12.04) 94.30 (11.43) 80.62 (12.22) 64 (21.59)
T3–T0 (n =
13) p-value
0.001 0.002 0.09 0.004 0.004 0.23 0.02 0.01
Active movement
T0 101.8 (52.74) 98.53 (42.79) 129.33 (13.11) 158.87 (28.13) 34.6 (37.44) 35.2 (32.91) 25.93 (26.52) 21.53 (19.10)
T1 113.87 (55.41) 110.2 (40.94) 137.27 (13.39) 164.6 (21.88) 41.73 (40.23) 41.8 (36.25) 36.33 (28.29) 25.6 (20.68)
T1–T0 (n =
15) p-value
b0.001 b0.001 b0.001 0.25 0.06 0.01 0.003 0.18
T2 106.33 (56.80) 104.5 (42.87) 138.67 (12.42) 164.83 (28.24) 36.58 (36.05) 42.17 (35.70) 37.75 (26.51) 26.67 (19.39)
T3 117.5 (52.37) 113.08 (39.81) 145.6 (11.42) 168.7 (24.69) 50.6 (37.18) 54.7 (31.10) 48.8 (28.15) 31.3 (19.10)
T3–T0 (n =
10) p-value
0.002 0.01 0.002 0.025 0.02 0.004 0.004 0.104
Modiﬁed Ashworth score
T0 3 (1) 3 (1) 2 (1) 2 (1) 2 (1) 2 (1) 2 (1) 2.5 (1)
T1 1 (2) 1 (2) 0 (1) 1 (0) 0 (1) 0.5 (2) 0 (1) 1 (2)
T1–T0 (n =
20) p-value
b0.001 b0.001 b0.001 b0.001 b0.001 b0.001 b0.001 b0.001
T2 1 (1) 1 (2) 0 (0) 1 (1) 0 (1) 1 (1) 0 (0) 2 (1)
T3 0 (1) 0 (1) 0 (0) 1 (1) 0 (0) 0 (2) 0 (0) 1 (2)
T3–T0 (n =
13) p-value
b0.001 b0.001 b0.001 b0.001 b0.001 0.001 b0.001 0.005
T0 = pre-injection; T1 = within 2 weeks post-injection; T2 = within 6–8 weeks post-injection; T3 = within 3–5 months post-injection.
311P. Raghavan et al. / EBioMedicine 9 (2016) 306–313paralysis, andmay trigger a cascade of events that leads to the accumu-
lation of hyaluronan (Stecco et al., 2014).
Furthermore, there is evidence for the role of transforming growth
factor-β (TGF-β), a proﬁbrotic cytokine, in the regulation of hyaluronan
production (Heldin et al., 1989; Westergren-Thorsson et al., 1990;
Dubaybo and Thet, 1990). Tissue injury, including cerebral injury,
leads to signiﬁcant increase in TGF-β locally (Logan et al., 1992; Wang
et al., 1995), where it may play a role in anti-inﬂammatory processes
and in brain tissue remodeling, as well as in the serum (Kaestner and
Dimitriou, 2013; Shi et al., 2015), where it may trigger catabolic signal-
ing for muscle atrophy (Springer et al., 2014; Budasz-Rwiderska et al.,Table 4
Correlation between baseline and change scores.
Passive movement
Correlation coefﬁcient p-Value Correlat
Correlation between baseline and short-term change
Shoulder ﬂexion 0.26 0.35
Shoulder abduction −0.20 0.48
Elbow ﬂexion −0.17 0.54
Elbow extension −0.86 b0.001
Forearm pronation 0.43 0.11
Forearm supination 0.57 0.03
Wrist ﬂexion 0.06 0.82
Wrist extension 0.19 0.49
Correlation between baseline and long-term change
Shoulder ﬂexion 0.20 0.58
Shoulder abduction −0.16 0.65
Elbow ﬂexion −0.01 0.99
Elbow extension −0.70 0.03
Forearm pronation −0.18 0.62
Forearm supination −0.13 0.72
Wrist ﬂexion −0.37 0.29
Wrist extension −0.18 0.63
Spearman's correlation for passive and active movement and modiﬁed Ashworth score betwee
change (T3–T0).2005), stimulate the production of hyaluronan (Al'Qteishat et al.,
2006), and the migration (Samuel et al., 1993) and differentiation of
myoﬁbroblasts leading to ﬁbrosis (Webber et al., 2009a, 2009b). More-
over, catabolism of hyaluronan by hyaluronidases (Colombaro et al.,
2015), and TGF-β antagonism (Midgley et al., 2015) can reduce the
levels of accumulated hyaluronan, potentially disrupting progression
to ﬁbrosis. Taken together, these ﬁndings support the Hyaluronan Hy-
pothesis of muscle stiffness and the treatment of muscle stiffness with
hyaluronidase.
Hyaluronidase is FDA-approved as an agent that enhances tissue
permeability, and it is currently indicated as an adjuvant to facilitateActive movement Modiﬁed Ashworth scale
ion coefﬁcient p-Value Correlation coefﬁcient p-Value
−0.13 0.58 −0.37 0.11
−0.17 0.48 −0.49 0.03
−0.62 0.004 −0.46 0.04
−0.19 0.42 −0.87 b0.001
−0.13 0.60 −0.75 b0.001
0.24 0.31 −0.52 0.02
−0.27 0.24 −0.61 0.004
0.08 0.75 −0.35 0.13
−0.40 0.18 −0.48 0.09
−0.28 0.35 −0.84 b0.001
−0.58 0.04 −0.04 0.88
−0.18 0.55 −0.85 b0.001
−0.65 0.017 −0.47 0.10
−0.18 0.55 −0.67 0.013
−0.68 0.011 −0.50 0.08
−0.22 0.47 −0.39 0.19
n pre-injection baseline (T0) and short-term change (T1–T0), and baseline and long-term
Table 5
Change in distribution of modiﬁed Ashworth scale (MAS) scores over time.
Time MAS = 0 MAS = 1 MAS = 1+ MAS = 2 MAS = 3
Total no.
of joints
assessed
T0 2 (1.3%) 3 (1.9%) 3 (1.9%) 81 (50.6%) 71 (44.4%) 160
T1 66 (48.2%) 41 (29.9%) 1 (0.7%) 21 (15.3%) 8 (5.8%) 137
T2 62 (59%) 26 (24.8%) 1 (1%) 14 (13.3%) 2 (1.9%) 105
T3 72 (45%) 53 (33.1%) 2 (1.3%) 31 (19.4%) 2 (1.3%) 160
T0= pre-injection; T1=within 2 weeks post-injection; T2=within 6–8 weeks post-in-
jection; T3 = within 3–5 months post-injection.
312 P. Raghavan et al. / EBioMedicine 9 (2016) 306–313the absorption of drugs. The action of hyaluronidase is short-lived; the
dermal barrier toﬂuid diffusion is partly restored in 24 h and completely
restored in 48 h following the administration of hyaluronidase
(Hechter, 1948). However, our results show noticeable and persistent
reduction in muscle stiffness after 48 h; this may suggest the presence
of hyaluronan cables (de la Motte et al., 2003; Lauer et al., 2013; Zhao
et al., 1995) in muscle stiffness that degrade slowly, and/or possible
cross-reactivity with chondroitinase (Stern and Jedrzejas, 2006). Bacte-
rial chondroitinase degrades scar tissue and promotes neural plasticity
after central nervous system damage in animal models (Fawcett,
2015). Hence longer-term results with hyaluronidase injections may
suggest interactions between non-neural muscle stiffness and neural
plasticity.
The efﬁcacy of treatment with hyaluronidase may be limited by the
degree of baseline stiffness, ﬁbrosis, and capacity for movement in spe-
ciﬁc directions. Increased stiffness in inter-connected synergistic mus-
cles may contribute to the ﬂexor synergy pattern, and chronic
abnormal posturing in shoulder adduction, elbow ﬂexion, and forearm
pronation is frequently seen in patients with spastic hemiparesis.
Some degree of ﬁbrosis in these muscles may limit the efﬁcacy of treat-
ment with hyaluronidase and explain the negative correlation between
baseline and long-term change scores on the Modiﬁed Ashworth scale
for shoulder abduction, elbow extension and forearm supination, and
thepositive correlationwith change in short-termpassive forearm supi-
nation. Thenegative correlation between baseline and change inpassive
elbow extension over the short- and long-term suggest ceiling effects as
most of the patients had almost full passive range at the elbow at base-
line. The negative correlations between baseline and change in active
elbow ﬂexion, forearm pronation, and wrist ﬂexion suggest greater ca-
pacity for movement in these directions.
Furthermore, stretching a stiff muscle either passively or actively
(for example, by contraction of the antagonist), will restrain the move-
ment due to increased tissue stiffness, and restrain the stretch due to in-
creased reﬂex contractions as a result of increased sensitivity of the
muscle spindles embedded in stiff tissue. Increased reﬂex contractions
may stimulate further production of hyaluronan (Stecco et al., 2011) in-
creasing connective tissue viscoelasticity and muscle stiffness. Since at-
tempts to stretch a muscle will invariable stretch multiple
interconnected synergist and antagonist muscles (Stecco, 2015), reduc-
tion of stiffness following restoration of intramuscular viscositymay not
persist without concurrent treatment of severalmuscles. In the ﬁrst few
patients we injected relatively fewmuscles, and subsequently increased
the number of muscles injected as we learnt that injectingmuscles both
proximal and distal to the primary stiff muscle, along the agonist and
antagonist myofascial chains of limb movement, can give more favor-
able results. An understanding of fascial planes and barriers to diffusion
of hyaluronidase, and a comprehensive and accurate selection of mus-
cles for injection are therefore important aspects of the treatment. Use
of tools such as ultrasonography or other imaging techniques to assess
the extent of ﬁbrosis could improve patient and muscle selection for
treatment.
So far, hyaluronidase has only been used for the treatment of muscle
stiffness at our clinic in New York. However, there are no technical lim-
itations that would prevent this procedure from being performed inother centers with similar expertise. The drug is available for off-label
use in the United States. A blinded randomized placebo-controlled
trial will be needed to control for a placebo response, the effects of con-
founding variables such as number and location of injection sites,
amount and quality of therapy, and investigator bias in recording and
analyzingmovement. This report does not address the effect of repeated
drug administration, although 15/20 patients did return for further in-
jections. The results of this study warrant replication by independent
groups.
Future studies should also directly investigate the role of hyaluronan
and hyaluronidase in changing the mechanical properties of spastic
muscles using simultaneous joint angle, torque, and EMG measure-
ments to tease apart the effects on spasticity versus stiffness, and exam-
ine the efﬁcacy of treatment with hyaluronidase on improvement in
motor control, prevention of muscle contracture, reduction in sensori-
motor impairment, and increase in quality of life. In addition the role
of cytokines such as TGF-β after cerebral injury inmediating sarcopenia,
accumulation of hyaluronan in muscle, and muscle contracture war-
rants further study.
This case series provides preliminary evidence for the safety and po-
tential efﬁcacy of hyaluronidase injections as a treatment for muscle
stiffness that may enhance functional recovery in the spastic upper
limb, and may be applicable to other disorders characterized by muscle
stiffness.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.05.014.
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